thalidomide has been researched along with Lymphoma, B-Cell in 30 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this review, the authors describe the pharmacological properties of lenalidomide, and the rational for its use in B-cell lymphomas; focusing on diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL)." | 8.93 | Lenalidomide for the treatment of B-cell lymphoma. ( Bouabdallah, R; Coso, D; Garciaz, S; Schiano de Colella, JM, 2016) |
| "The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide." | 7.73 | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. ( Bicciato, S; Corradini, P; Dammacco, F; Di Pietro, G; Mattioli, M; Montefusco, V; Neri, A; Nico, B; Ribatti, D; Scavelli, C; Vacca, A, 2005) |
| "In this review, the authors describe the pharmacological properties of lenalidomide, and the rational for its use in B-cell lymphomas; focusing on diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL)." | 4.93 | Lenalidomide for the treatment of B-cell lymphoma. ( Bouabdallah, R; Coso, D; Garciaz, S; Schiano de Colella, JM, 2016) |
| "Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma." | 4.91 | A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. ( Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE, 2015) |
| "The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide." | 3.73 | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. ( Bicciato, S; Corradini, P; Dammacco, F; Di Pietro, G; Mattioli, M; Montefusco, V; Neri, A; Nico, B; Ribatti, D; Scavelli, C; Vacca, A, 2005) |
| "To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma." | 2.82 | [Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. ( Yang, YZ, 2016) |
| "Lenalidomide is an immunomodulatory drug with effects on the immune system that may enhance antibody-dependent cell-mediated cytotoxicity and reverse tumor-induced immune suppression." | 2.79 | Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. ( Ahmadi, T; Aqui, NA; Chong, EA; Gordon, A; Mato, AR; Nasta, SD; Schuster, SJ; Svoboda, J, 2014) |
| "Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression." | 2.74 | Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. ( Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB, 2009) |
| "Lenalidomide is an oral immunomodulatory drug with significant activity in indolent B-cell and mantle cell lymphomas." | 2.53 | Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. ( Martin, P; Ruan, J; Schuster, SJ; Shah, B, 2016) |
| "Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic activity and indirect effects mediated through multiple types of immune cells found in the tumor microenvironment, including B, T, natural killer (NK), and dendritic cells." | 2.52 | Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. ( Fowler, N; Gribben, JG; Morschhauser, F, 2015) |
| "Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB)." | 1.32 | Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. ( Baird, R; Duddy, J; Iveson, A; Rassam, SM; van Zyl-Smit, RN, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lian, K | 3 |
| Zhang, QH | 3 |
| Hou, SL | 3 |
| Li, L | 3 |
| Sun, Y | 1 |
| Zhao, X | 1 |
| Ding, N | 1 |
| Gao, H | 1 |
| Wu, Y | 1 |
| Yang, Y | 1 |
| Zhao, M | 1 |
| Hwang, J | 1 |
| Song, Y | 1 |
| Liu, W | 1 |
| Rao, Y | 1 |
| Hitz, F | 2 |
| Fischer, N | 2 |
| Pabst, T | 2 |
| Caspar, C | 1 |
| Berthod, G | 1 |
| Eckhardt, K | 2 |
| Berardi Vilei, S | 2 |
| Zucca, E | 2 |
| Mey, U | 2 |
| Ahmadi, T | 2 |
| Chong, EA | 2 |
| Gordon, A | 1 |
| Aqui, NA | 2 |
| Nasta, SD | 2 |
| Svoboda, J | 2 |
| Mato, AR | 2 |
| Schuster, SJ | 3 |
| Maddocks, K | 1 |
| Blum, KA | 1 |
| Cai, Q | 1 |
| Chen, Y | 1 |
| Zou, D | 1 |
| Zhang, L | 1 |
| Badillo, M | 1 |
| Zhou, S | 1 |
| Lopez, E | 1 |
| Jiang, W | 1 |
| Huang, H | 1 |
| Lin, T | 1 |
| Romaguera, J | 1 |
| Wang, M | 1 |
| Walsh, KM | 1 |
| Witzig, TE | 1 |
| Nowakowski, GS | 1 |
| Habermann, TM | 2 |
| Goy, A | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Chiappella, A | 1 |
| Vitolo, U | 1 |
| Fowler, N | 2 |
| Czuczman, MS | 1 |
| Gribben, JG | 1 |
| Morschhauser, F | 1 |
| Salihoglu, A | 1 |
| Ar, MC | 1 |
| Soysal, T | 1 |
| Yang, YZ | 1 |
| Hayashi, K | 1 |
| Nagasaki, E | 1 |
| Kan, S | 1 |
| Ito, M | 1 |
| Kamata, Y | 1 |
| Homma, S | 1 |
| Aiba, K | 1 |
| Cairoli, A | 1 |
| Samaras, P | 1 |
| Caspar, CB | 1 |
| Mach, N | 1 |
| Krasniqi, F | 1 |
| Schmidt, A | 1 |
| Rothermundt, C | 1 |
| Enoiu, M | 1 |
| Rondeau, S | 1 |
| Ruan, J | 1 |
| Shah, B | 1 |
| Martin, P | 1 |
| Garciaz, S | 1 |
| Coso, D | 1 |
| Schiano de Colella, JM | 1 |
| Bouabdallah, R | 1 |
| Lossos, IS | 1 |
| Justice, G | 1 |
| Vose, JM | 1 |
| Wiernik, PH | 2 |
| McBride, K | 1 |
| Wride, K | 1 |
| Ervin-Haynes, A | 1 |
| Takeshita, K | 1 |
| Pietronigro, D | 1 |
| Zeldis, JB | 1 |
| Tuscano, JM | 1 |
| Civallero, M | 2 |
| Cosenza, M | 2 |
| Bari, A | 2 |
| Sacchi, S | 2 |
| Ohmachi, K | 1 |
| Grisendi, G | 1 |
| Marcheselli, L | 1 |
| Roat, E | 1 |
| Ogura, M | 1 |
| Jäger, U | 1 |
| Goldman, B | 1 |
| Baird, R | 1 |
| van Zyl-Smit, RN | 1 |
| Iveson, A | 1 |
| Duddy, J | 1 |
| Rassam, SM | 1 |
| Schlenzka, J | 1 |
| Moehler, TM | 1 |
| Kipriyanov, SM | 1 |
| Kornacker, M | 1 |
| Benner, A | 1 |
| Bähre, A | 1 |
| Stassar, MJ | 1 |
| Schäfer, HJ | 1 |
| Little, M | 1 |
| Goldschmidt, H | 1 |
| Cochlovius, B | 1 |
| Vacca, A | 1 |
| Scavelli, C | 1 |
| Montefusco, V | 1 |
| Di Pietro, G | 1 |
| Neri, A | 1 |
| Mattioli, M | 1 |
| Bicciato, S | 1 |
| Nico, B | 1 |
| Ribatti, D | 1 |
| Dammacco, F | 1 |
| Corradini, P | 1 |
| Tueger, S | 1 |
| Chen, FE | 1 |
| Ahsan, G | 1 |
| McDonald, V | 1 |
| Andrews, VE | 1 |
| Madrigal, JA | 1 |
| Kazmi, MA | 1 |
| Darabi, K | 1 |
| Kantamnei, S | 1 |
| Verhelle, D | 1 |
| Corral, LG | 1 |
| Wong, K | 1 |
| Mueller, JH | 1 |
| Moutouh-de Parseval, L | 1 |
| Jensen-Pergakes, K | 1 |
| Schafer, PH | 1 |
| Chen, R | 1 |
| Glezer, E | 1 |
| Ferguson, GD | 1 |
| Lopez-Girona, A | 1 |
| Muller, GW | 1 |
| Brady, HA | 1 |
| Chan, KW | 1 |
| Menon, S | 1 |
| Habermann, T | 1 |
| Witzig, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.[NCT00987493] | Phase 1/Phase 2 | 49 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma[NCT01476787] | Phase 3 | 255 participants (Actual) | Interventional | 2011-12-29 | Active, not recruiting | ||
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for thalidomide and Lymphoma, B-Cell
| Article | Year |
|---|---|
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clin | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2015 |
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 2015 |
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
Topics: Angiogenesis Inhibitors; B-Lymphocytes; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgki | 2015 |
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Drug Resistance, Neoplasm; Drug-Relat | 2016 |
Lenalidomide for the treatment of B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Hum | 2016 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; | 2011 |
8 trials available for thalidomide and Lymphoma, B-Cell
| Article | Year |
|---|---|
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combin | 2014 |
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neo | 2015 |
[Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; La | 2016 |
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bend | 2016 |
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Ad | 2009 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydro | 2012 |
15 other studies available for thalidomide and Lymphoma, B-Cell
| Article | Year |
|---|---|
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurr | 2023 |
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; H | 2018 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic | 2016 |
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2011 |
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolif | 2012 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2003 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; A | 2003 |
Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia.
Topics: Adult; Fatal Outcome; Female; Humans; Leukemia, Erythroblastic, Acute; Lymphoma, B-Cell; Meningeal N | 2004 |
Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma.
Topics: Animals; Antibodies, Bispecific; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Dru | 2004 |
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Cells, Cultured; Culture Media | 2005 |
Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Humans; Lymphoma, B-Cell; Lymphoma, Large B | 2006 |
Lenalidomide-induced warm autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lenalidomide; Lymphoma, B-Cell; Thalidomide | 2006 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, | 2007 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, | 2007 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, | 2007 |
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; B-Lymphocytes; Cell Cycle; Cell Growth Processes; Cell Line, | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Lenalidomide-associated hypothyroidism.
Topics: Antineoplastic Agents; Female; Humans; Hypothyroidism; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Lar | 2007 |